Telix Pharmaceuticals Advances Prostate Cancer Trial in U.S. After FDA Alignment

Telix Pharmaceuticals has reached an agreement with the U.S. FDA to proceed with Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx, a treatment for metastatic castration-resistant prostate cancer. The FDA confirmed that initial safety data supports advancing the trial in the U.S. and aligned on key aspects of the study protocol.